Mandate

Vinge has advised the owners of Swedish Oat Fiber in conjunction with the sale of the company to Naturex

November 14, 2017 Banking and Finance

Swedish Oat Fiber has a leading international market position as a producer of oat beta glucan, dietary fiber, oat oils and oat proteins for use in the food, health, cosmetics and animal food industries. The company’s head office and manufacturing facility is situated in Bua outside Gothenburg.

Naturex distributes, manufactures and markets natural special ingredients for the food, health and cosmetics industries. Naturex is listed on Euronext Paris and has its head office in Avignon, France, and employs 1 700 people over the entire world. In 2016, the group’s turnover was EUR 404.4 million. The acquisition accords with Naturex’s strategy to accelerate the development of its special production portfolio and will provide significant synergies with their business development model. Swedish Oat Fiber will also contribute to strengthening Naturex’s market position within the natural food segment.

Vinge’s team consisted of partner Björn Mullaart together with, among others, associates Fredrik Christiansson, Niklas Törnell and Freja Ljungdell Kristensen.

Livingstone acted as the financial advisor to Swedish Oat Fiber in the sales process.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024